NovoCure Ltd 8-K

What Happened

• NovoCure Ltd held its annual general meeting on June 3, 2026 and filed an 8-K on June 5, 2026 reporting the results. Shareholders elected 11 directors — Asaf Danziger, William Doyle, Jeryl Hilleman, David Hung, Frank Leonard, Kinyip Gabriel Leung, Martin Madden, Allyson Ocean, Timothy Scannell, Kristin Stafford and William Vernon — effective immediately for terms expiring at the 2027 annual meeting. The company reported no related-party transactions for these directors and said they will be paid under existing non-employee director compensation programs.
• Several other proposals were voted on and approved: ratification of Kost Forer Gabbay & Kasierer (a member of Ernst & Young Global) as the independent registered public accounting firm for fiscal 2026, a non-binding advisory vote to approve executive compensation (say-on-pay), and the Company’s Amended and Restated 2024 Omnibus Incentive Plan.

Key Details

• Shares present/voted: 93,826,730 shares (≈81.01% of voting shares) at the AGM.
• Director vote examples: Asaf Danziger — For 81,489,609; Against 1,388,512; William Doyle — For 80,241,009; Against 2,664,190 (full tallies for each director reported in the filing).
• Auditor ratification: For 91,436,910; Against 2,337,255; Abstain 52,565.
• Omnibus Plan approval was narrow: For 41,680,622; Against 41,161,139; Abstain 110,839; broker non‑votes 10,874,130 — the plan received just over 50% of votes cast for/against.

Why It Matters

• Board continuity: Election of the full slate of directors confirms governance continuity and identifies the group responsible for oversight through 2027. No related-party disclosures were reported for these directors in the filing.
• Compensation and dilution: Approval of the amended Omnibus Incentive Plan allows the company to grant equity and other incentive awards under the updated plan; the very close vote indicates meaningful shareholder opposition which investors may watch as a signal of concern about compensation practices or potential dilution.
• Audit oversight: Ratification of the auditor is routine but important for financial reporting continuity going into fiscal 2026.

Filed: Form 8-K dated June 5, 2026 (Annual Meeting held June 3, 2026).